Two-Year Data of Evrysdi™ (risdiplam) in Infants with Spinal Muscular Atrophy Demonstrate Continued Improvement of Developmental Milestones
(World News Brazil)

PDF Version - Patients in Part 1 of the FIREFISH study demonstrated gains in motor milestones between months 12 and 24 - - Strong Evrysdi™ launch following approval with broad label - SOUTH PLAINFIELD, N.J., Sept. 28, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that two-year data from Part 1 of the FIREFISH study demonstrated that infants on Evrysdi™ (risdiplam) continued to improve and achieve motor milestones. Evrysdi™ was approved in August for the treatment of spinal muscular atrophy (SMA) patients two months and older. Data were presented at the 25th International Annual Congress of the World Muscle Society (WMS). `The results from the long-term FIREFISH...